^
    Back
    Association details:
    Biomarker:TFRC overexpression + PD-L1 underexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancers (Basel)
    Title:

    Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression

    Published date:
    09/07/2023
    Excerpt:
    Higher baseline TFRC levels predicted a favorable response to nivolumab in NSCLC with low PD-L1 expression.
    DOI:
    https://www.mdpi.com/2072-6694/15/18/4460